Compare Global X Copper Miners ETF (COPX) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Copper Miners ETF vs Sana Biotechnology Inc — how do they compare? Global X Copper Miners ETF trades at $88.62, while Sana Biotechnology Inc trades at $3.77 (market cap $1.13B). The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals.
| COPX | SANA | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $95.70 | $5.92 |
52-Week Low | $46.08 | $2.68 |
Market Cap | — | $1.13B |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COPX (Global X Copper Miners ETF) trades at $88.51, down 1.12% today, while maintaining a bullish technical outlook with strong moving average signals. The ETF offers exposure to copper miners benefiting from AI-driven demand for electrification infrastructure. Recent institutional buying includes 180 Wealth Advisors increasing its position by 28.1% in Q2 2026 (SEC filing, August 2026). Technical indicators show overbought RSI levels but strong trend momentum with ADX readings.
The copper mining sector faces structural demand growth from AI data center expansion and electrification trends, though mining equities currently trade at a discount to copper futures. Supply constraints and cyclical volatility present risks, but analyst sentiment remains positive for long-term exposure to copper's role in the energy transition.
SANA Biotechnology trades at $3.77, up 4.43% today, with a bullish technical signal from moving averages and ADX indicators. The company reported a net loss of $244.17 million for 2025, with negative cash flow from operations, but analyst consensus is strongly positive with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 average price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress driving future profitability, but high cash burn and negative ROE pose significant risks. Upside potential exists if pipeline milestones are met, supported by institutional optimism, though investors face volatility from earnings misses and funding needs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Global X Copper Miners ETF
COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
